- BioMarin Pharmaceutical ( NASDAQ: BMRN ) said that an updated Institute for Clinical and Economic Review (ICER) Draft Evidence Report on gene therapy Roctavian for hemophilia A provides substantial cost savings and projected gains in quality adjusted life years .
- The report compared one-time administration of Roctavian versus Hemlibra (emicizumab), made by Roche's ( OTCQX:RHHBY ) Genentech unit, prophylaxis. ICER assumed annual cost of Hemlibra at $640K and one-time Roctavian at $2.5M.
- Results showed that Roctavian provided a $4M cost saving per patient over a lifetime with projected improvement in quality of life compared to Hemlibra.
- Also, ICER took into account an outcomes-based warranty agreement which BioMarin ( BMRN ) plans to offer that will allow risk sharing for four years and have it ready for payers at launch.
- Seeking Alpha's Quant Rating views BioMarin ( BMRN ) as a hold with high marks for growth and profitability .
For further details see:
BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A